Regulation 57 Gradual introduction of premises approval
Where a dispensing doctor (D) has outline consent but F1NHS England considers that the provision of pharmaceutical services by any NHS pharmacist, or of LP services by any LPS chemist, is likely to be adversely affected if D provides pharmaceutical services F2at or from medical practice premises which have been subject to a related application for premises approval (whether under regulation 51, 54 or 55), NHS England may by conditions—
postpone the taking effect of the related premises approval for such period as it thinks fit; or
limit the patients to whom D (or any successor to D) is able to provide pharmaceutical services F3at or from the medical practice premises in such manner, and for such periods, as it thinks fit.
NHS England must decide whether or not to impose conditions under paragraph (1)—
if there was a delay in the related outline consent taking effect because of an outstanding pharmacy application, when it determines that the outline consent is to come into effect; or
in any other case, when it determines the application for premises approval.
NHS England must notify any decision to impose, or not to impose, conditions under paragraph (1) to—
D;
any person with third party appeal rights in relation to the related application for premises approval;
any Local Pharmaceutical Committee whose area includes the medical practice premises to which the decision relates; and
any Local Medical Committee whose area includes the medical practice premises to which the decision relates.
A notification under paragraph (3) must include—
a statement of the reasons for the decision; and
if the person notified is a person with rights of appeal under regulation 63(1)(f), an explanation of how those rights may be exercised.
Annotations
Textual amendments
- F1
Words in Regulations substituted (6.11.2023) by The Health and Care Act 2022 (Further Consequential Amendments) (No. 2) Regulations 2023 (S.I. 2023/1071), reg. 1(1), Sch. para. 1
- F2
Words in reg. 57(1) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 37(a)
- F3
Words in reg. 57(1)(b) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 37(b)